SONOSCAPE(SZ:300633) Sou Hu Cai Jing·2026-01-22 12:46Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with revenue growth but significant declines in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of January 22, 2026, Kaili Medical's stock closed at 28.11 yuan, with a slight increase of 0.14% [1]. - The turnover rate was 0.7%, with a trading volume of 30,100 hands and a transaction amount of 84.89 million yuan [1]. - On January 22, the net inflow of main funds was 3.33 million yuan, accounting for 3.93% of the total transaction amount [1]. - Retail investors experienced a net outflow of 4.20 million yuan, representing 4.94% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 10 institutions provided ratings for Kaili Medical, with 8 giving a "buy" rating and 2 giving an "accumulate" rating [2]. - The average target price set by institutions over the past 90 days is 39.71 yuan [2].